337 related articles for article (PubMed ID: 31190789)
1. Targeting IL-5 in COPD.
Narendra DK; Hanania NA
Int J Chron Obstruct Pulmon Dis; 2019; 14():1045-1051. PubMed ID: 31190789
[TBL] [Abstract][Full Text] [Related]
2. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
3. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease.
Mkorombindo T; Dransfield MT
Int J Chron Obstruct Pulmon Dis; 2019; 14():1779-1787. PubMed ID: 31496677
[TBL] [Abstract][Full Text] [Related]
4. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease.
Tashkin DP; Wechsler ME
Int J Chron Obstruct Pulmon Dis; 2018; 13():335-349. PubMed ID: 29403271
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
[TBL] [Abstract][Full Text] [Related]
6. The role of interleukin 5 in asthma.
Varricchi G; Canonica GW
Expert Rev Clin Immunol; 2016 Sep; 12(9):903-5. PubMed ID: 27450970
[No Abstract] [Full Text] [Related]
7. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
Bel EH; Ten Brinke A
Chest; 2017 Dec; 152(6):1276-1282. PubMed ID: 28583618
[TBL] [Abstract][Full Text] [Related]
8. Sputum
George L; Wright A; Mistry V; Sutcliffe A; Chachi L; Haldar K; Ramsheh MY; Richardson M; van der Merwe R; Martin U; Newbold P; Brightling CE
Int J Chron Obstruct Pulmon Dis; 2019; 14():1177-1185. PubMed ID: 31239655
[TBL] [Abstract][Full Text] [Related]
9. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
Kim JE; Lee DH; Jung K; Kim EJ; Choi Y; Park HS; Kim YS
Front Immunol; 2020; 11():593748. PubMed ID: 33488590
[TBL] [Abstract][Full Text] [Related]
10. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.
Matucci A; Maggi E; Vultaggio A
Respir Med; 2019; 160():105819. PubMed ID: 31734469
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations.
Fernandez Romero GA; Beros J; Criner G
Expert Rev Respir Med; 2019 Feb; 13(2):125-132. PubMed ID: 30570418
[TBL] [Abstract][Full Text] [Related]
13. Benralizumab: for asthma, not yet for COPD.
Fabbri LM
Lancet Respir Med; 2014 Nov; 2(11):862-863. PubMed ID: 25306558
[No Abstract] [Full Text] [Related]
14. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
15. Benralizumab: First Global Approval.
Markham A
Drugs; 2018 Mar; 78(4):505-511. PubMed ID: 29464664
[TBL] [Abstract][Full Text] [Related]
16. Biologic Drugs: A New Target Therapy in COPD?
Yousuf A; Brightling CE
COPD; 2018 Apr; 15(2):99-107. PubMed ID: 29683730
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab for the treatment of severe eosinophilic asthma.
Poulakos MN; Cargill SM; Waineo MF; Wolford AL
Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
[TBL] [Abstract][Full Text] [Related]
18. Biologic Therapy in Chronic Obstructive Pulmonary Disease.
Tripple JW; McCracken JL; Calhoun WJ
Immunol Allergy Clin North Am; 2017 May; 37(2):345-355. PubMed ID: 28366481
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
